SEC Tracker
Get the app

Edgewise Therapeutics EWTX

Edgewise Therapeutics reports Q3 2026 financial results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash and investments: $1.74 billion as of Sept 30, 2026
  2. Net income: $1.166 billion for Q3 2026
  3. R&D expenses: $31.6 million for Q3 2026
  4. Gain on sevasemten sale: $1.348 billion

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Edgewise Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The filing includes a press release announcing these results, which is attached as Exhibit 99.1.
  2. The press release in Item 2.02 of the Form 8-K details the company's financial results for the third quarter of 2026.
  3. The press release is incorporated by reference into the filing.
  4. The Form 8-K also includes Item 9.01, which lists financial statements and exhibits.
  5. Exhibit 99.1 is the press release, and Exhibit 104 is the cover page interactive data file.
  6. The filing was signed by the Chief Financial Officer, Michael Nofi, on November 4, 2026.

6 of 6 claims matched the filing text.

For perspective, checked against its own source

From the 10-Q for the quarter ended June 30, 2026

  • In its 10-Q for the quarter ended June 30, 2026, Edgewise Therapeutics, Inc. reported a net income of -$57.3 million.

From the filing

Item 2.02 Results of Operations and Financial Condition.

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2026, Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the third quarter ended September2

30, 20262. The full text of the press release is attached hereto as Exhibit 99.11 and is incorporated herein by reference3.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01

Item 9.014

Financial4

Statements and Exhibits4.

(d)

Exhibits.

Exhibit No.

Description

99.15

Press Release of Edgewise Therapeutics, Inc. dated November 4, 20265

1045

Cover Page Interactive Data File (embedded within the Inline XBRL documents)5

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EDGEWISE THERAPEUTICS, INC.

By:6

/s/ Michael Nofi6

Michael Nofi6

Chief Financial Officer6

Date: November 4, 20266

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Innoviva INVA public float $1.3B, Jun 30, 2025
  2. Mannkind MNKD public float $1.1B, Jun 30, 2025
  3. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  4. Ani Pharmaceuticals ANIP public float $1.3B, Jun 30, 2025
  5. Celldex Therapeutics CLDX public float $1.3B, Jun 30, 2025